Nanostructure enhanced targeting (NSET) of inflammatory cells
The present invention provides nanomaterials for the specific targeting of immune cells. Methods of treating cardiac disease and inflammatory disease are also described.
1. A method of targeting an agent to dendritic cells in a subject having or suspected of having cardiovascular disease, the method comprising
administering to the subject a polymersome comprising block copolymers of polyethylene glycol) (PEG) and polypropylene sulfide) (PPS) incorporating or encapsulating a statin for the diagnosis or treatment of cardiovascular disease, wherein the polymersome targets dendritic cells within the subject.
2. The method of claim 1 , wherein the polymersome comprises a vesicular polymer membrane comprising PEG 17 -bl-PPS 30 .
3. The method of claim 1 , wherein the size of the polymersome is about 90 to about 150 nm in diameter, and wherein the statin is delivered to dendritic cells within the blood vessels of the subject and ameliorates at least one symptom of cardiovascular disease.
4. The method of claim 1 , wherein the cardiovascular disease comprises atherosclerotic lesions.
5. The method of claim 1 , wherein the polymersome does not contain a targeting ligand specific for dendritic cells.
6. The method of claim 1 , wherein the polymersomes increase the specific uptake of an agent by dendritic cells within the blood vessels by at least 20% as compared to the agent alone.
7. The method of claim 1 , the method further comprising:
selecting a subject having or suspected of having atherosclerotic lesions prior to the administering step.
8. A method of targeting an agent to dendritic cells within atherosclerotic lesions in a subject having or suspected of having atherosclerotic lesions, the method comprising
administering to the subject a polymersome comprising block copolymers of poly(ethylene glycol) (PEG) and polypropylene sulfide) (PPS), the polymersome incorporating or encapsulating a statin for the diagnosis or treatment of atherosclerotic lesions, wherein the polymersome targets dendritic cells within the subject.
9. The method of claim 8 , wherein the polymersome comprises PEG 17 -bl-PPS 30 .
10. The method of claim 8 , wherein the size of the polymersome is about 90 to about 150 nm in diameter, and wherein the agent is delivered to dendritic cells within the blood vessels of the subject and ameliorates at least one symptom of cardiovascular disease.